Anti-Human MUC1 (CD227) – Dylight® 488

Anti-Human MUC1 (CD227) – Dylight® 488

Product No.: M468

- -
- -
Clone
HMFG2
Target
CD227 (MUC1)
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
HMFG2, MUC1, CD227
Isotype
Mouse IgG1 L
Applications
ELISA
,
FC
,
IHC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
MUC1 (CD227)
Product Concentration
0.5 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Excitation Laser
Blue Laser (493 nm)
Additional Applications Reported In Literature ?
IHC
ELISA
WB
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
HMFG2 activity is directed against human MUC1 (CD227).
Background
MUC1 is a large, highly glycosylated transmembrane mucin which contains a very large extracellular domain of 1000-2200 amino acids consisting primarily of 20 amino acid tandem repeats 1. MUC1 is a member of a family of related cell surface epithelial mucins 1,2 and is structurally related to hemopoietic and endothelial sialomucins such as GlyCAM1 and MadCAM-1 2.

MUC1 forms part of the mucous gel that covers the external surface of epithelial tissues and acts as a barrier to infection 1. Additionally, MUC1 is involved in signal transduction via its highly conserved cytoplasmic tail, which is tyrosine phosphorylated in activated dendritic cells and T cells 2, and binds all members of the ErbB family of receptor tyrosine kinases as well as β-catenin 1. Additionally, there is interest in using MUC1 as a target antigen for cancer immunotherapy for carcinomas and multiple myeloma 2, due to variations in glycosylation that can be present in cancer 1.

HMFG2 was generated by immunizing BALB/c mice with delipidated human milk fat globule (HMFG) containing the intact mucin, and subsequently immunizing with mammary epithelial cells 3. Spleen cells were fused with myeloma line P3/NSl/l-Ag4-1 to create hybridomas, which were screened for specificity against epithelial cells. HMFG2 reacts with an underglycosylated MUC1 mucin 4 and recognizes oligosaccharide sequences containing galactose, N-acetyl glucosamine and N-acetyl galactosamine, specifically the DTR sequence of the core protein 5. Binding to the core-protein epitopes is influenced by the length of the carbohydrate side chains 6.
Antigen Distribution
MUC1 is a cell surface antigen expressed on mucosal epithelial tissues, T cells, B cells, bone marrow mononuclear cells, human blood dendritic cells, and monocyte-derived dendritic cells following in vitro activation. MUC1 is also found in the cytoplasm and cytoplasmic membrane of ductal cells, primarily in the striated ducts of the parotid and submandibular human glands and in the secretory compartment.
Ligand/Receptor
ICAM-1 and Her2/neu (ErbB2)
NCBI Gene Bank ID
UniProt.org
Research Area
Biomarker
.
Cancer
.
Immunology

References & Citations

1. Ponce-Bravo S, Ledesma-Montes C, Morales-Sánchez I. APMIS. 116(2):93-98. 2008.
2. Wykes M, MacDonald KP, Tran M, et al. J Leukoc Biol. 72(4):692-701. 2002.
3. Taylor-Papadimitriou J, Peterson JA, Arklie J, et al. Int J Cancer. 28(1):17-21. 1981.
4. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Cancer Res. 47(20):5476-5482. 1987.
5. Burchell J, Durbin H, Taylor-Papadimitriou J. J Immunol. 131(1):508-513. 1983.
6. Burchell J, Taylor-Papadimitriou J. Epithelial Cell Biol. 2(4):155-162. 1993.
7. Price MR, Edwards S, Owainati A, et al. Int J Cancer. 36(5):567-574. 1985.
8. Schettini J, Kidiyoor A, Besmer DM, et al. Cancer Immunol Immunother. 61(11):2055-2065. 2012.
9. Arklie J, Taylor-Papadimitrious J, Bodmer W, et al. Int J Cancer. 28(1):23-29. 1981.
10. Berry N, Jones DB, Smallwood J, et al. Br J Cancer. 51(2):179-186. 1985.
11. Heyderman E, Strudley I, Powell G, et al. 52(3):355-361. 1985.
12. Demichelis SO, Alberdi CG, Servi WJ, et al. Appl Immunohistochem Mol Morphol. 18(1):41-50. 2010.
13. Beckford U, Barbatis C, Beesley JE, et al. J Clin Pathol. 38(5):512-520. 1985.
14. Ormerod MG, Steele K, Edwards PA, et al. J Exp Pathol. 1(4):263-271. 1984.
15. Dhokia B, Canney PA, Pectasides D, et al. Br J Cancer. 54(6):891-895. 1986.
16. Epenetos AA, Shepherd J, Britton KE, et al. Cancer. 55(5):984-987. 1985.
17. Singer S, Boddington MM, Hudson EA. J Clin Pathol. 38(2):180-184. 1985.
18. Epenetos AA, Hooker G, Krausz T, et al. Obstet Gynecol. 68(3 Suppl):71S-74S. 1986.
19. Swallow DM, Griffiths B, Bramwell M, et al. Dis Markers. 4(4):247-254. 1986.
Indirect Elisa Protocol
Flow Cytometry
IHC
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.